All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How can we predict drug resistance in high-risk MDS?

During the 16th International Congress on Myelodysplastic Syndromes (MDS 2021), the MDS hub was pleased to speak to Mikkael Sekeres, Sylvester Comprehensive Cancer Center, Miami, US. We asked, how can we predict drug resistance in high-risk MDS?

How can we predict drug resistance in high-risk MDS?

In this video, Sekeres explains the methods of predicting how patients with MDS will respond to hypomethylating agents, such as screening for the presence of specific mutations and the use of artificial intelligence.

 

Share: